Sunflower Therapeutics Receives NIH SBIR Funding to Develop an Automated, Continuous Cell Disruption Platform for VLP-Based Vaccine Manufacturing
Platform to advance the large-scale production and purification of virus-like particles (VLPs) for use in cost-effective human vaccines MEDFORD, Mass.–(BUSINESS WIRE)–Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse…